Abstract

CLINICAL EVALUATION FENUGREEK SEED EXTRACT IN PATIENTS WITH TYPE-2 DIABETES: AN ADD-ON STUDY IN 154 PATIENTS

Prof. Narsingh Verma*, Dr. Kauser Usman, Vandana Awasthi, Pawan K Goel, Gopesh Lamgora

Abstract

Diabetes is an epidemic disease and is considered as the major cause of mortality and morbidity across globe. The global increase in the prevalence of diabetes is due to the combination of causes such as population growth, aging, unplanned fast urbanization and an increase in obesity and physical inactivity. Addition of fenugreek seed extract in the diet may reduce blood sugar and urine sugar levels along with improvement in glucose tolerance in type-2 diabetic patients. The present study was an add-on, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of the standardized fenugreek seed extract as furostenolic saponins. It included the oral administration of Fenugreek seed extract (Fenfuro) in 154 patients suffering from type-2 diabetes mellitus were randomized in two groups. One group of patients received Fenfuro and the other group received Placebo. The subjects were assed clinically and biochemically at pre-defined intervals of 4 weeks during 12 weeks study. Fenfuro effectively caused significant change in blood glucose levels, decrease in HbA1c levels, fasting plasma glucose levels, PP plasma glucose levels and increase in C-peptide levels as compared to Placebo group. Fenfuro-treated group also showed reduction in concomitant anti-diabetic therapy. This fenugreek preparation was also found to be safe in patients with type-2 diabetes as depicted by the safety parameters.

Keywords: furostenolic saponins, (Fenfuro).